# Indalo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indalo-therapeutics

- Industry: Pharmaceuticals
- Headquarters: St. Louis, US
- Website: www.indalotherapeutics.com
- Total disclosed funding: $26M
- Latest round: Series A (Jan 28, 2019)
- Investors on record: 6

## About

Based in Missouri, US, and founded in 2016, Indalo Therapeutics, Inc operates as a biopharmaceutical company that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm was founded as a merger between Cascadian Therapeutics, Inc., and Antegrin Therapeutics LLC. In January 2019, Indalo Therapeutics, Inc. raised USD 26 million in series A funding co-led by Atlas Venture and Atlas Venture, Missouri Technology Corporation, and BioGenerator.

The company's IDL-2965 is an oral, selective antagonist of RGD-binding integrins avb1, avb3, and avb6 that inhibits numerous stages of pathologic fibrosis, including the local stimulation of TGF-b by both epithelial cells and fibroblasts.

## Funding rounds

- Series A, Jan 28, 2019, $17M — Atlas Venture, F-Prime Capital, BioGenerator, Missouri Technology Corporation, iSelect Fund Management
- Series A, Jun 30, 2017, $9M — Atlas Venture, F-Prime Capital, BioGenerator, Missouri Technology Corporation, Argonautic Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series A
- Missouri Technology Corporation — Series A
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A
- iSelect Fund Management (https://capitalatlas.ai/funds/iselect-fund-management) — Series A